Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.67 |
| ▸ | GUSB | P08236 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | THRB | P10828 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | KIF11 | P52732 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14413867 | 0.88 | ALDH1A1 (0.70) | GAAKMT2AADORA2BTSHRALDH1A1 | |
| SCHEMBL19752615 | 0.88 | ALDH1A1 (0.70) | GAAKMT2AADORA2BTSHRALDH1A1 | |
| SCHEMBL29506643 | 0.88 | ALDH1A1 (0.70) | GAAKMT2AADORA2BTSHRALDH1A1 | |
| SCHEMBL10113433 | 0.86 | CTDSP1 (0.54) | CTDSP1GUSBGAAKMT2ATSHR | |
| SCHEMBL10279779 | 0.86 | USP2 (0.58) | CTDSP1GAAKMT2APKMTSHR | |
| SCHEMBL19732961 | 0.86 | USP2 (0.58) | CTDSP1GAAKMT2APKMTSHR | |
| SCHEMBL19752674 | 0.84 | USP2 (0.71) | GUSBKMT2APKMADORA2BTSHR | |
| SCHEMBL5327469 | 0.84 | USP2 (0.71) | GUSBKMT2APKMADORA2BTSHR | |
| SCHEMBL19752617 | 0.84 | ALDH1A1 (0.53) | CTDSP1GAAALDH1A1KIF11 | |
| SCHEMBL28595517 | 0.82 | ALDH1A1 (0.78) | GUSBGAAKMT2APKMTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9815838-B2 | Methods and compositions for treating pain | HYDRA BIOSCIENCES, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815838-B2 | Methods and compositions for treating pain | HYDRA BIOSCIENCES, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20140221401-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | HYDRA BIOSCIENCES, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221401-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | HYDRA BIOSCIENCES, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| EP-1962855-B1 | TRPA1 INHIBITORS FOR TREATING PAIN | HYDRA BIOSCIENCES INC (US) | 2013-08-21 | — | — | EP | disclosed |
| US-8389529-B2 | Methods and compositions for treating asthma | HYDRA BIOSCIENCES, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389529-B2 | Methods and compositions for treating asthma | HYDRA BIOSCIENCES, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-7671061-B2 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671061-B2 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-20070219222-A1 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070219222-A1 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219222-A1 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | TRPA1, TRPV1, TRPV2 | CTDSP1 4445/4885GUSB 580/4885GAA 2708/4885 |
| US-20140221401-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | ACHE, COL2A1, MMP8 | CTDSP1 3440/4885GUSB 26/4885GAA 876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.